Drugs / Bryostatin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03560245 | Jun 2018 → Jul 2019 | Alzheimer disease | Neurotrope Bioscience, Inc. | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bryostatin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03560245 ↗ |
| Route | Intravenous | “Drug is administered IV by continuous infusion over 45(±5) minutes.” NCT03560245 ↗ |